by dyadic | Feb 24, 2020 | Press Releases
Further Extends Company’s Biologic Market Opportunities JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. (“Dyadic”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1...
by dyadic | Feb 5, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / February 5, 2020 / Dyadic International, Inc. (the “Company”) (NASDAQ:DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following investor conferences: BIO CEO &...
by dyadic | Jan 31, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...
by dyadic | Jan 28, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...
by dyadic | Jan 27, 2020 | Press Releases
JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...
by dyadic | Jan 6, 2020 | Press Releases
Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Leading Pharmaceutical Company IIBR Collaboration Achieved Expression of Fc-fusion Enzyme...
